Research programme: metabolic disorders therapeutics - Juvena Therapeutics
Latest Information Update: 24 Nov 2023
Price :
$50 *
At a glance
- Originator Juvena Therapeutics
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Metabolic disorders
Highest Development Phases
- Research Metabolic disorders
Most Recent Events
- 19 Oct 2023 M 11 is available for licensing as of 19 Oct 2023. https://www.juvenatherapeutics.com/our-science/
- 19 Oct 2023 Juvena Therapeutics has patent pending for drug discovery and development platform in USA (Juvena Therapeutics pipeline, October 2023)
- 19 Oct 2023 Early research in Metabolic disorders in USA (unspecified route) (Juvena Therapeutics pipeline, October 2023)